Background Cancer mortality rates, though not absolute numbers of deaths, have been
decreasing over the last three decades in Europe. Materials and methods We estimated …

Chronic lymphocytic leukaemia (CLL) is a malignancy of clonally expanded antigen-
switched, neoplastic, mature B cells. CLL is characterised by a variable degree of …

Background We predicted cancer mortality figures for 2024 for the European Union (EU), its
five most populous countries, and the UK. We focused on mortality from colorectal cancer …

Simple Summary High-throughput CRISPR screening provides an unbiased way for
functional genomic studies in hematological malignancies. This approach has been used to …

BIRC3 is monoallelically deleted in up to 80% of chronic lymphocytic leukemia (CLL) cases
harboring del (11q). In addition, truncating mutations in the remaining allele of this gene can …

Background We predicted cancer mortality figures for 2023 for the European Union (EU-27),
its five most populous countries, and the UK. We also focused on mortality from lung cancer …

Simple Summary To our knowledge, this is the first study to use free text from electronic
healthcare records as a data source extracted with natural language processing to …

Background Most patients with chronic lymphocytic leukaemia progress after treatment or
retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent …

Objective The purpose of this analysis was to assess health-related quality of life (HRQoL) in
patients treated with zanubrutinib and ibrutinib in the ALPINE trial (NCT03734016). Methods …

Interstitial 14q32 deletions involving IGH gene are infrequent events in chronic lymphocytic
leukemia (CLL), affecting less than 5% of patients. To date, little is known about their clinical …